Seladelpar 5 mg Capsule + Seladelpar 10 mg Capsule
Phase 3Active 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Biliary Cirrhosis
Conditions
Primary Biliary Cirrhosis
Trial Timeline
Dec 12, 2017 → Nov 1, 2028
NCT ID
NCT03301506About Seladelpar 5 mg Capsule + Seladelpar 10 mg Capsule
Seladelpar 5 mg Capsule + Seladelpar 10 mg Capsule is a phase 3 stage product being developed by Gilead Sciences for Primary Biliary Cirrhosis. The current trial status is active. This product is registered under clinical trial identifier NCT03301506. Target conditions include Primary Biliary Cirrhosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03301506 | Phase 3 | Active |
Competing Products
20 competing products in Primary Biliary Cirrhosis